

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

ATHEROGENICS INC  
Form SC 13G/A  
February 14, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. 4 )\*

ATHEROGENICS, INC.  
(Name of Issuer)

Common Stock, no par value  
(Title of Class of Securities)

047439104  
(CUSIP Number)

December 31, 2006  
(Date of Event which Requires Filing  
of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Continued on following pages  
Page 1 of 11 Pages  
Exhibit Index: Page 9

SCHEDULE 13G/A

CUSIP No. 047439104

Page 2 of 11 Pages

1 Names of Reporting Persons  
I.R.S. Identification Nos. of above persons (entities only)

Atticus Capital LP

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

2 Check the Appropriate Box If a Member of a Group (See Instructions)  
a.  [ ]  
b.  [ ]

3 SEC Use Only

4 Citizenship or Place of Organization

Delaware

Number of Shares Beneficially Owned By Each Reporting Person With	5	Sole Voting Power 5,577,060
	6	Shared Voting Power 0
	7	Sole Dispositive Power 5,577,060
	8	Shared Dispositive Power 0

9 Aggregate Amount Beneficially Owned by Each Reporting Person

5,577,060

10 Check Box If the Aggregate Amount in Row (9) Excludes Certain  
Shares (See Instructions)

[ ]

11 Percent of Class Represented By Amount in Row (9)

14.11%

12 Type of Reporting Person (See Instructions)

PN

CUSIP No. 047439104

Page 3 of 11 Pages

1 Names of Reporting Persons  
I.R.S. Identification Nos. of above persons (entities only)

Atticus Management LLC

2 Check the Appropriate Box If a Member of a Group (See Instructions)  
a.  [ ]  
b.  [ ]

3 SEC Use Only

4 Citizenship or Place of Organization

Delaware

Number of Shares	5	Sole Voting Power 5,577,060
---------------------	---	--------------------------------

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

Beneficially Owned By Each Reporting Person With	6	Shared Voting Power 0
	7	Sole Dispositive Power 5,577,060
	8	Shared Dispositive Power 0
9	Aggregate Amount Beneficially Owned by Each Reporting Person  5,577,060	
10	Check Box If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  [ ]	
11	Percent of Class Represented By Amount in Row (9)  14.11%	
12	Type of Reporting Person (See Instructions)  OO	

SCHEDULE 13G/A

CUSIP No. 047439104

Page 4 of 11 Pages

1	Names of Reporting Persons I.R.S. Identification Nos. of above persons (entities only)  Timothy R. Barakett	
2	Check the Appropriate Box If a Member of a Group (See Instructions) a. [ ] b. [ ]	
3	SEC Use Only	
4	Citizenship or Place of Organization  Canada	
	5	Sole Voting Power 5,577,060
Number of Shares	6	Shared Voting Power 0
Beneficially Owned By Each Reporting Person With	7	Sole Dispositive Power 5,577,060
	8	Shared Dispositive Power  0

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

9 Aggregate Amount Beneficially Owned by Each Reporting Person  
5,577,060

10 Check Box If the Aggregate Amount in Row (9) Excludes Certain  
Shares (See Instructions)  
[ ]

11 Percent of Class Represented By Amount in Row (9)  
14.11%

12 Type of Reporting Person (See Instructions)  
HC

SCHEDULE 13G/A

CUSIP No. 047439104

Page 5 of 11 Pages

Item 1(a) Name of Issuer:

Atherogenics, Inc. (the "Issuer").

Item 1(b) Address of the Issuer's Principal Executive Offices:

8995 Westside Parkway  
Alpharetta, Georgia 30004

Item 2(a) Name of Person Filing:

This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

- i) Atticus Capital LP ("Atticus Capital");
- ii) Atticus Management LLC ("Atticus Management"); and
- iii) Timothy R. Barakett ("Mr. Barakett").

Effective as of January 1, 2006, Atticus Management (f/k/a Atticus Capital, L.L.C.) effected a restructuring in which it assigned to Atticus Capital its rights and obligations under the investment management agreements with its clients and following the restructuring it changed its name to "Atticus Management LLC." Mr. Barakett is the Chairman, Chief Executive Officer and Managing Member of Atticus Management, a Delaware limited liability company. Atticus Management is the sole general partner of Atticus Capital, a Delaware limited partnership. Atticus Capital, together with certain of its affiliated entities (collectively, the "Atticus Entities"), acts as adviser for various investment funds (the "Funds") and managed accounts (the "Accounts"). Based on his relationship with the Atticus Entities, the Funds and the Accounts, Mr. Barakett is deemed to be a beneficial owner of the Shares owned by the Funds and Accounts for purposes of Section 13(d) of the Act.

Item 2(b) Address of Principal Business Office or, if None, Residence:

## Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

The address of the principal business office of the Reporting Persons is 152 West 57th Street, 45th Floor, New York, NY 10019.

Item 2(c) Citizenship:

- 1) Atticus Capital is a Delaware limited partnership;
- 2) Atticus Management is a Delaware limited liability company;  
and
- 3) Mr. Barakett is a citizen of Canada.

Item 2(d) Title of Class of Securities:

Common Stock, no par value (the "Shares").

Item 2(e) CUSIP Number:

047439104

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

This Item 3 is not applicable.

### SCHEDULE 13G/A

CUSIP No. 047439104

Page 6 of 11 Pages

Item 4. Ownership:

Item 4(a) Amount Beneficially Owned:

As of the Date of Event, each of the Reporting Persons may be deemed to be the beneficial owner of 5,577,060 Shares.

Item 4(b) Percent of Class:

Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 14.11% of the total number of Shares outstanding.

Item 4(c) Number of shares as to which such person has:

Atticus Capital  
-----

(i)	Sole power to vote or direct the vote	5,577,060
(ii)	Shared power to vote or to direct the vote	0
(iii)	Sole power to dispose or to direct the disposition of	5,577,060
(iv)	Shared power to dispose or to direct the disposition of	0

Atticus Management  
-----

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

(i)	Sole power to vote or direct the vote	5,577,060
(ii)	Shared power to vote or to direct the vote	0
(iii)	Sole power to dispose or to direct the disposition of	5,577,060
(iv)	Shared power to dispose or to direct the disposition of	0

Mr. Barakett  
-----

(i)	Sole power to vote or direct the vote	5,577,060
(ii)	Shared power to vote or to direct the vote	0
(iii)	Sole power to dispose or to direct the disposition of	5,577,060
(iv)	Shared power to dispose or to direct the disposition of	0

Item 5. Ownership of Five Percent or Less of a Class:

This Item 5 is not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

This Item 6 is not applicable.

SCHEDULE 13G/A

CUSIP No. 047439104

Page 7 of 11 Pages

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

This Item 7 is not applicable.

Item 8. Identification and Classification of Members of the Group:

This Item 8 is not applicable.

Item 9. Notice of Dissolution of Group:

This Item 9 is not applicable.

Item 10. Certification:

By signing below each of the Reporting Persons certifies that, to the best of such person's knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

SCHEDULE 13G/A

CUSIP No. 047439104

Page 8 of 11 Pages

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2007

ATTICUS CAPITAL LP

By: Atticus Management LLC,  
its general partner

By: /s/ John F. Brown\*

-----  
Name: Timothy R. Barakett  
Title: Managing Member

Date: February 14, 2007

ATTICUS MANAGEMENT LLC

By: /s/ John F. Brown\*

-----  
Name: Timothy R. Barakett  
Title: Managing Member

Date: February 14, 2007

TIMOTHY R. BARAKETT

/s/ John F. Brown\*  
-----

\*By John F. Brown, attorney-in-fact

SCHEDULE 13G/A

CUSIP No. 047439104

Page 9 of 11 Pages

EXHIBIT INDEX

	Page No.
A. Joint Filing Agreement, dated as of February 14, 2007, by and among Atticus Capital LP, Atticus Management LLC and Timothy R. Barakett.....	10
B. Power of Attorney, dated January 18, 2007.....	11

Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

SCHEDULE 13G/A

CUSIP No. 047439104

Page 10 of 11 Pages

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that Amendment No. 4 to the Schedule 13G with respect to the Common Stock, no par value per share, of Atherogenics, Inc., dated as of February 14, 2007, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.

Date: February 14, 2007

ATTICUS CAPITAL LP

By: Atticus Management LLC,  
its general partner

By: /s/ John F. Brown\*

-----  
Name: Timothy R. Barakett  
Title: Managing Member

Date: February 14, 2007

ATTICUS MANAGEMENT LLC

By: /s/ John F. Brown\*

-----  
Name: Timothy R. Barakett  
Title: Managing Member

Date: February 14, 2007

TIMOTHY R. BARAKETT

/s/ John F. Brown\*  
-----

\*By John F. Brown, attorney-in-fact

SCHEDULE 13G/A

CUSIP No. 047439104

Page 11 of 11 Pages

EXHIBIT B

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that I, TIMOTHY R. BARAKETT, hereby make, constitute and appoint each of JOHN F. BROWN, DENNIS BERTRON and CHARLES FORTIN, acting individually, as my agent and attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my



Edgar Filing: ATHEROGENICS INC - Form SC 13G/A

capacity as chief executive officer of, managing member of or in other capacities with Atticus Capital LP or its general partner, Atticus Management LLC (f/k/a Atticus Capital, L.L.C.) (collectively, "Atticus"), and each of their affiliates, including Atticus UK LLP and Atticus UK Services Ltd., and entities advised by me or Atticus, all documents, certificates, instruments, statements, filings and agreements ("documents") to be filed with or delivered to any foreign or domestic governmental or regulatory body or required or requested by any other person or entity pursuant to any legal or regulatory requirement relating to the acquisition, ownership, management or disposition of securities, futures contracts or other investments, and any other documents relating or ancillary thereto, including without limitation all documents relating to filings with the Commodities Futures Trading Commission and National Futures Association, the United States Securities and Exchange Commission (the "SEC") pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934 (the "Act") and the rules and regulations promulgated thereunder, including all documents relating to the beneficial ownership of securities required to be filed with the SEC pursuant to Section 13(d) or Section 16(a) of the Act and any information statements on Form 13F required to be filed with the SEC pursuant to Section 13(f) of the Act. All past acts of the attorneys-in-fact in furtherance of the foregoing are hereby ratified and confirmed.

THIS POWER OF ATTORNEY shall remain in full force and effect until either revoked in writing by the undersigned or until such time as the person or persons to whom power of attorney has been hereby granted cease(s) to be an employee of, or otherwise associated with, Atticus or one of its affiliates. Execution of this power of attorney revokes that certain Power of Attorney dated as of March 21, 2006 with respect to substantially the same matters addressed above.

IN WITNESS WHEREOF, the undersigned has duly subscribed these presents as of January 18, 2007.

/s/ Timothy R. Barakett

-----  
Timothy R. Barakett